ALX Oncology (ALXO) Competitors $1.21 -0.02 (-1.63%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALXO vs. NGNE, ATYR, FATE, PYXS, BMEA, TRVI, BNTC, ACB, TCRX, and STROShould you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Neurogene (NGNE), Atyr PHARMA (ATYR), Fate Therapeutics (FATE), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), Trevi Therapeutics (TRVI), Benitec Biopharma (BNTC), Aurora Cannabis (ACB), TScan Therapeutics (TCRX), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry. ALX Oncology vs. Neurogene Atyr PHARMA Fate Therapeutics Pyxis Oncology Biomea Fusion Trevi Therapeutics Benitec Biopharma Aurora Cannabis TScan Therapeutics Sutro Biopharma Neurogene (NASDAQ:NGNE) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, NGNE or ALXO? Neurogene has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Does the MarketBeat Community favor NGNE or ALXO? ALX Oncology received 22 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 62.67% of users gave ALX Oncology an outperform vote. CompanyUnderperformOutperformNeurogeneOutperform Votes25100.00% Underperform VotesNo VotesALX OncologyOutperform Votes4762.67% Underperform Votes2837.33% Does the media favor NGNE or ALXO? In the previous week, Neurogene had 15 more articles in the media than ALX Oncology. MarketBeat recorded 23 mentions for Neurogene and 8 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.51 beat Neurogene's score of 0.27 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral ALX Oncology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NGNE or ALXO more profitable? Neurogene's return on equity of -32.81% beat ALX Oncology's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -32.81% -27.96% ALX Oncology N/A -93.02%-70.67% Do institutionals & insiders hold more shares of NGNE or ALXO? 52.4% of Neurogene shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 9.9% of Neurogene shares are held by company insiders. Comparatively, 33.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer NGNE or ALXO? Neurogene currently has a consensus price target of $60.83, suggesting a potential upside of 296.83%. ALX Oncology has a consensus price target of $12.50, suggesting a potential upside of 933.06%. Given ALX Oncology's higher probable upside, analysts plainly believe ALX Oncology is more favorable than Neurogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11ALX Oncology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable earnings & valuation, NGNE or ALXO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogeneN/AN/A-$36.32MN/AN/AALX OncologyN/AN/A-$160.80M-$2.98-0.41 SummaryNeurogene beats ALX Oncology on 9 of the 14 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get ALX Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALXO vs. The Competition Export to ExcelMetricALX OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.87M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.414.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book0.4710.126.936.25Net Income-$160.80M$153.61M$119.12M$225.93M7 Day Performance-9.02%-2.00%-1.83%-1.32%1 Month Performance-19.33%-7.47%-3.64%0.60%1 Year Performance-86.78%31.80%31.64%26.23% ALX Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALXOALX Oncology3.3343 of 5 stars$1.21-1.6%$12.50+933.1%-87.7%$64.87MN/A-0.4140NGNENeurogene2.9326 of 5 stars$15.33-11.0%$60.83+296.8%N/A$255.95MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageATYRAtyr PHARMA3.0032 of 5 stars$2.99-1.6%$19.25+543.8%N/A$255.18M$350,000.00-3.1856FATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$248.29M$63.53M0.00550Analyst UpgradePYXSPyxis Oncology1.0178 of 5 stars$3.82-8.2%$9.57+150.6%+165.3%$247.38MN/A-3.7160News CoverageGap UpHigh Trading VolumeBMEABiomea Fusion3.4326 of 5 stars$6.28-2.2%$30.50+385.7%-39.1%$232.65MN/A-1.5750TRVITrevi Therapeutics3.4138 of 5 stars$2.77-7.7%$7.43+168.2%+113.1%$230.60MN/A-6.3020BNTCBenitec Biopharma2.2984 of 5 stars$10.66+7.9%$22.60+112.0%+202.8%$229.38M$80,000.000.0020Positive NewsHigh Trading VolumeACBAurora Cannabis0.6402 of 5 stars$4.24+1.4%N/A-11.0%$229.24M$200.35M0.001,073TCRXTScan Therapeutics2.9905 of 5 stars$4.12-2.1%$12.00+191.3%-10.6%$223.02M$21.05M0.00100STROSutro Biopharma4.5351 of 5 stars$2.67-1.1%$12.14+354.8%-3.6%$222.64M$153.73M0.00240Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Neurogene Competitors Atyr PHARMA Competitors Fate Therapeutics Competitors Pyxis Oncology Competitors Biomea Fusion Competitors Trevi Therapeutics Competitors Benitec Biopharma Competitors Aurora Cannabis Competitors TScan Therapeutics Competitors Sutro Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALXO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALX Oncology Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ALX Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
